Last reviewed · How we verify
BuCy vs BuFlu
BuCy and BuFlu are conditioning regimens that use chemotherapy agents (busulfan combined with either cyclophosphamide or fludarabine) to prepare patients for hematopoietic stem cell transplantation by suppressing bone marrow and the immune system.
BuCy and BuFlu are conditioning regimens that use chemotherapy agents (busulfan combined with either cyclophosphamide or fludarabine) to prepare patients for hematopoietic stem cell transplantation by suppressing bone marrow and the immune system. Used for Conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for hematologic malignancies, Conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for severe aplastic anemia.
At a glance
| Generic name | BuCy vs BuFlu |
|---|---|
| Also known as | busulfan plus cyclophosphamide versus fludarabine |
| Sponsor | Cooperative Study Group A for Hematology |
| Drug class | Chemotherapy conditioning regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology / Hematology |
| Phase | Phase 3 |
Mechanism of action
BuCy (busulfan-cyclophosphamide) and BuFlu (busulfan-fludarabine) are myeloablative or reduced-intensity conditioning regimens used prior to allogeneic hematopoietic stem cell transplantation. Busulfan is an alkylating agent that damages DNA and destroys bone marrow cells, while cyclophosphamide or fludarabine provide additional immunosuppression and cytotoxic effects. These regimens eliminate residual disease and create space for donor stem cell engraftment.
Approved indications
- Conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for hematologic malignancies
- Conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for severe aplastic anemia
Common side effects
- Mucositis
- Myelosuppression
- Hepatic veno-occlusive disease
- Infection
- Graft-versus-host disease
- Nausea and vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BuCy vs BuFlu CI brief — competitive landscape report
- BuCy vs BuFlu updates RSS · CI watch RSS
- Cooperative Study Group A for Hematology portfolio CI